In this phase 2 study presented at ADA 2023, oral nonpeptide GLP-1 receptor agonist orforglipron led to significant reductions in body weight, BMI, and waist circumference in adults with obesity or overweight and at least one comorbidity. All doses of orforglipron outperformed placebo at week 26, with up to 75% of participants achieving ≥10% weight loss. The treatment was well tolerated, with a safety profile similar to other GLP-1 receptor agonists.
Read this publication to explore:
- Efficacy outcomes by dose, including weight, BMI, and waist circumference
- Proportion of participants reaching ≥5% and ≥10% weight loss
- Safety and GI tolerability during dose escalation